Commitments and contingencies	12 Months Ended
Commitments and contingencies	Sep. 30, 2013
Commitments and contingencies [Abstract]
Commitments and contingencies	22. Commitments and contingencies Legal proceedings: On March 6, 2013, as a result of the Company's inability to pay approximately $30 million of senior secured debt which had become due on November 17, 2012, the Company filed a voluntary petition to reorganize under Chapter 11 of the U.S. Bankruptcy Code with Case No.8:13-bk-02892-KRM. After confirmation hearings on May 31, 2013 and June 10, 2013, the Bankruptcy Court confirmed the First Amended Plan of Reorganization, (as amended and modified, the "Plan"), and entered an Order Confirming the Plan on June 28, 2013. The Plan became effective on July 9, 2013. Two Notices of Appeal of provisions of the Bankruptcy Proceedings were filed by the Equity Committee during the pendency of the 2013 Bankruptcy Proceedings; both appeals were dismissed for lack of prosecution and mootness, as the Equity Committee had been dissolved as of the effectiveness of the Plan and no party had taken action to be substituted in to continue to pursue these appeals. This Chapter 11 case was concluded via Final Decree by the Bankruptcy Court entered on September 30, 2013. On July 24, 2013 and August 5, 2013, purported class actions were filed in the United States District Court for the Middle District of Florida (Tampa Division) against Biovest's former parent corporation, Accentia, and several current and former directors and officers of Biovest and Accentia (the "Class Action"). Biovest was not named as a defendant in either complaint. The complaints allege that the defendants violated federal securities laws by making or causing Accentia and/or Biovest to make false statements, and by failing to disclose or causing Accentia and/or Biovest to fail to disclose material information, concerning the results of the Phase III clinical trial of BiovaxID and status of its approval by the FDA. Plaintiffs seek damages in an unspecified amount on behalf of shareholders who purchased common stock of Accentia or Biovest between July 24, 2008 and August 14, 2012 and were damaged as a result of the decline in the price of common stock allegedly attributable to the claimed violations. On December 4, 2013 the District Court entered an Order consolidating the Class Action cases and appointing a group of lead plaintiffs, beginning a 45-day period during which a Consolidated Complaint must be filed and served. Although the time to respond to this Class Action complaint is still underway, our officers and directors believe this litigation to be without merit, deny any wrongdoing or liability and intend to vigorously defend the alleged claims. The Company is not party to any material legal proceedings, and management is not aware of any other, threatened legal proceedings that could cause a material adverse impact on our business, assets, or results of operations. Further, from time to time we are subject to various legal proceedings in the normal course of business, some of which are covered by insurance. Facility leases: The Company leases approximately 35,000 square feet in Minneapolis (Coon Rapids), Minnesota, which the Company uses for offices, laboratory, manufacturing, and warehousing space to support its development, potential commercialization, and production of BiovaxID, the production of the Company's perfusion cell culture equipment, and the Company's contract cell culture services. The lease expires on July 30, 2021 (Note 8). The Company has the right to extend the term of the lease. As of April 10, 2013, the Company entered into a new lease for approximately 1,300 square feet of office space in Tampa, Florida and utilizes the space as the Company's principal executive and administrative offices. The lease expires on December 31, 2014 and is cancelable by either party with 90 days prior notice. Future minimum lease payments related to this lease total $30 thousand and $7 thousand during the years ending September 30, 2014 and 2015, respectively. The Company plans to continue to evaluate its requirements for facilities during fiscal 2014. The Company anticipates that as its development of its product candidates advances and as the Company prepares for the future commercialization of its products, its facilities requirements will continue to change on an ongoing basis. Stanford University Agreement: In September 2004, the Company entered into an agreement, and amended on September 6, 2012, (collectively, the "Stanford Agreement") with Stanford University ("Stanford"). The Stanford Agreement provides the Company with worldwide rights to use two proprietary hybridoma cell lines, which are used in the production of the BiovaxID through 2025. Under the Stanford Agreement, the Company is obligated to pay an annual maintenance fee of $0.01 million. The Stanford Agreement also provides that the Company pays Stanford $0.1 million within one year following FDA approval of BiovaxID. Following FDA approval until September 17, 2019, Stanford will receive a royalty of the greater of $50 per patient or 0.05% of BiovaxID net sales revenue, after September 18, 2019, Stanford will receive a royalty of the greater of $85 per patient or 0.10% of BiovaxID net sales revenue. This running royalty will be creditable against the yearly maintenance fee. The Stanford Agreement obligates the Company to, diligently develop, manufacture, market, and sell BiovaxID and to provide progress reports to Stanford regarding these activities. The Company can terminate the Stanford Agreement at any time upon 30 days prior written notice, and Stanford can terminate the Stanford Agreement upon a breach of the agreement by the Company that remains uncured for 30 days after written notice of the breach from Stanford. Royalty Agreements: The aggregate royalty obligation on BiovaxID (including the Stanford royalty above) and the Company's other biologic products is 6.30% of BiovaxID net sales revenue. Food and Drug Administration: The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which mammalian proteins will be manufactured. Any new bioproduct intended for use in humans (including, to a somewhat lesser degree, in vivo biodiagnostic products), is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bioproducts (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company's cell culture systems used for the production of therapeutic or biotherapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended. Product liability: The contract production services for therapeutic products offered exposes an inherent risk of liability as the proteins or other substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company obtains agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company's operations.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

BIOVEST INTERNATIONAL INC 10-K